Visual outcomes following bilateral implantation of two diffractive trifocal IOLs in 10,084 eyes

Session Details

Session Title: Pseudophakic IOLs: Multifocal I

Session Date/Time: Sunday 08/10/2017 | 08:00-10:00

Paper Time: 08:40

Venue: Room 2.1

First Author: : R.Bilbao-Calabuig SPAIN

Co Author(s): :    F. Gonzalez-Lopez   A. LLovet-Rausell   J. Ortega-Usobiaga   F. LLovet-Osuna           

Abstract Details

Purpose:

To investigate refractive and visual acuity outcomes, patient satisfaction and spectacle independence of two diffractive non-toric trifocal IOLs in a large series of patients.

Setting:

Clínica Baviera centers, Spain

Methods:

Multicenter, retrospective analysis: patients underwent lens phacoemulsification and were implanted bilaterally with a diffractive trifocal IOL: FineVision MicroF or AT Lisa tri 839MP. 10,084 trifocal IOLs were implanted (5,802 FineVision in 2901 patients and 4,282 AT Lisa in 2141 patients). Surgeries were performed between 2011 and 2015. Visual and refractive performance, patient satisfaction and spectacle independence were evaluated after at least three months of follow-up.

Results:

AT Lisa, binocular uncorrected distance visual acuity (UDVA), -0.01 logMAR ±0.06 (SD); monocular distance corrected visual acuity (CDVA), 0.02 logMAR±0.06; binocular uncorrected near visual acuity (UNVA), 0.05 logMAR ±0.08; binocular uncorrected intermediate visual acuity (UIVA), -0.05 logMAR ±0.14; postoperative spherical equivalent, 0.26 D ±0.47. FineVision Micro F, binocular UDVA, 0.01 logMAR ±0.05 ; monocular CDVA, 0.03 logMAR ±0.06; binocular UNVA, 0.05 logMAR ±0.08 ; binocular UIVA, -0.05 logMAR ±0.12; spherical equivalent, 0.34 D ±0.50. Both IOLs were equivalent in achieving spectacle independence; 98% said that they were “satisfied” to “very satisfied” with their IOL performance.

Conclusions:

In this large retrospective case series study, implantation of both trifocal IOL models provided excellent distance, intermediate and near visual acuity, resulting in high levels of both spectacle independence and patient satisfaction.

Financial Disclosure:

NONE